Check4™ for Cancer Gene Mutations

About IdentifySensors

IdentifySensors is pioneering a novel digital diagnostics platform centered on its Check4™ system, which utilizes solid-state, graphene-based biosensors for direct molecular recognition. The platform is initially focused on detecting clinically actionable cancer mutations (e.g., EGFR, KRAS) with the goal of enabling rapid therapy selection, resistance monitoring, and minimal residual disease assessment. As a platform technology, it is designed to expand into multiplex testing for infectious diseases and other biomarkers, operating on a SaaS business model. The company is in the development stage, having initiated FDA submissions in Q2 2025, and is positioning itself to address the need for affordable, decentralized, and rapid molecular testing.

Therapeutic Areas